**Core tip:** Since the promulgation of the eighth edition of the American Joint Committee on Cancer staging system manual (AJCC-8^th^), it has attracted the attention of many clinicians around the world and guided clinical work. Using our institution data we explored the prognostic differences between AJCC-8^th^ and the seventh edition of the AJCC manual (AJCC-7^th^) for colorectal cancer. We found that patients with stage IVC colorectal cancer have a worse prognosis. This shows that peritoneal metastasis has a worse prognosis than organ metastasis. Considering many prognostic factors, individualized treatment is particularly important to improve the survival time of stage IV patients, especially stage IVC patients.

INTRODUCTION
============

Colorectal cancer (CRC) is a common malignant tumor\[[@B1]-[@B2]\]. In 2016, the incidence and mortality in the United States were respectively ranked fourth and second\[[@B3]-[@B7]\]. In 2015, 376000 patients were newly diagnosed with CRC in China and 191000 patients died from the disease\[[@B8]\]. Surgical resection remains the mainstay of treatment for local and regional disease\[[@B9]-[@B14]\]. Adjuvant chemotherapy is frequently used in advanced colon cancer and CRC, but remains controversial for stage II disease\[[@B15]-[@B21]\]. Understanding the pathologic staging in conjunction with prognostic values is essential to making therapeutic decisions. The American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging model has provided this universal modality since its first edition in 1977\[[@B22]\]. Since then, the AJCC has repeatedly revised this guideline (Figure [1](#F1){ref-type="fig"}) to continuously guide clinical treatment.

![The progression of American Joint Committee on Cancer tumor staging. AJCC: American Joint Committee on Cancer.](WJCO-9-148-g001){#F1}

The eighth edition of the AJCC staging system (AJCC-8^th^) was released on October 6, 2016 in Chicago, IL, United States, and was implemented globally on January 1, 2018, which included significant changes for CRC patients with stage IV disease\[[@B23]\]. The Cancer Council under the American College of Surgeons required the use of the AJCC-8^th^ staging system as the "primary language" for cancer reporting. In 2013, AJCC established the "Evidence-Based Medicine and Statistics Core Group" of the 8^th^ edition of the staging system. The organization is composed of clinical physicians, statisticians, and methodologists. It is responsible for determining the level of evidence for any updated content of the AJCC staging system.

The level of evidence is divided into four levels, and the quality of evidence represented by it gradually decreases from level I to level IV. Level I requires that the evidence is from multiple large national or international studies, has consistent results, has good research requirement design and implementation, was conducted in appropriate patient populations with appropriate study endpoints and appropriate treatment options, either as prospective studies or review-based studies based on patient populations, but all studies must be methodologically assessed. Level II requires that the evidence comes from at least one large study and had good design and implementation, was conducted in a suitable patient population with a suitable study endpoint, and has external reliability (generally the representative and extrapolated capabilities of the study are better). Level III includes evidence from a study with certain flaws, defects in the number of possible subjects, size, or quality of the study, or the consistency of multiple findings, the appropriateness of the patient population, and the appropriateness of the results. Level IV includes evidence wherein no reasonable research had been done. Only evidence from levels I-III could be included in the 8th version of the staging system.

A major difference between AJCC-7^th^, and AJCC-8^th^ is that the CRC staging system was revised to include a new stage involving peritoneal metastasis (named stage IVC) (see Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} for details). Based on a variety of evidence-based medical evidence\[[@B24],[@B25]\], the AJCC-8^th^ CRC staging system continues to recommend vascular lymphatic vessel infiltration and tumor deposition as prognostic level information, while microsatellite instability status and *BRAF* gene status are used as prognostic factors, and *BRAF*, *KRAS*, and degeneration of the *NRAS* gene were used as a predictor of efficacy (Table [3](#T3){ref-type="table"})\[[@B26]\].

###### 

Comparison of the tumor-node-metastasis stages between the 7^th^ edition and the 8^th^ edition

  **7^th^ edition**                                                                                                                          **8^th^ edition**
  ------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------
  Tx: Primary tumor cannot be assessed                                                                                                       Tx: Primary tumor cannot be assessed
  T0: No evidence of primary tumor                                                                                                           T0: No evidence of primary tumor
  Tis: Carcinoma *in situ*, limited to intraepithelial or invasive lamina propria                                                            Tis: Carcinoma *in situ*, limited to intraepithelial or invasive lamina propria
  T1: Tumor invading submucosa                                                                                                               T1: Tumor invading submucosa
  T2: Tumor invading the muscularis propria                                                                                                  T2: Tumor invading the muscularis propria
  T3: Tumor penetrating the muscularis propria and arriving at colorectal fat tissue                                                         T3: Tumor penetrating the muscularis propria and arriving at colorectal fat tissue
  T4: Tumor directly invading other organs or structures                                                                                     T4: Tumor directly invading other organs or structures
  T4a: Tumor penetrating visceral peritoneum                                                                                                 T4a: Tumor penetrating visceral peritoneum
  T4b: Tumor directly invading or adhering to other organs or structures                                                                     T4b: Tumor directly invading or adhering to other organs or structures
  Nx: Regional lymph nodes cannot be assessed                                                                                                Nx: Regional lymph nodes cannot be assessed
  N0: No lymph node metastasis and no tumor deposits (TD)                                                                                    N0: No lymph node metastasis and no TD
  N1: 1-3 lymph nodes metastases                                                                                                             N1: 1-3 lymph nodes metastases
  N1a: 1 lymph node metastases                                                                                                               N1a: 1 lymph node metastases
  N1b: 2-3 lymph nodes metastases                                                                                                            N1b: 2-3 lymph nodes metastases
  N1c: Although there was no regional lymph node metastasis, TDs were submucosal, mesangial, or peritoneum-covered para-colorectal tissue.   N1c: Although there was no regional lymph node metastasis, TDs were submucosal, mesangial or peritoneum-covered para-colorectal tissue.
  N2: More than or equal to 4 lymph node metastases                                                                                          N2: More than or equal to 4 lymph node metastases
  N2a: 4-6 regional lymph node metastases                                                                                                    N2a: 4-6 regional lymph node metastases
  N2b: More than or equal to 7 lymph node metastases                                                                                         N2b: More than or equal to 7 lymph node metastases
  M1: There is distant lymph node metastasis                                                                                                 M1: There is distant lymph node metastasis
  M1a: Metastasis is limited to one organ or site (*e.g*., liver, lung, ovary, and extra-regional lymph node metastases)                     M1a: Metastasis is limited to one organ or site (*e.g*., liver, lung, ovary, and extra-regional lymph node metastases)
  M1b: Transfer more than one organ or site, or to the peritoneum[1](#T1FN1){ref-type="table-fn"}                                            M1b: Transfer more than one organ or site[1](#T1FN1){ref-type="table-fn"}
                                                                                                                                             M1c: Peritoneal metastases with or without metastasis of other organs[1](#T1FN1){ref-type="table-fn"}

Differences between the two versions.

###### 

Colorectal cancer tumor-node-metastasis staging American Joint Committee on Cancer 7^th^ and 8^th^ editions

  **7^th^ edition**   **8^th^ edition**                                            
  ------------------- ------------------- -------- ------- ------ ------- -------- -----
  0                   Tis                 N0       M0      0      Tis     N0       M0
  I                   T1-2                N0       M0      I      T1-2    N0       M0
  IIA                 T3                  N0       M0      IIA    T3      N0       M0
  IIB                 T4a                 N0       M0      IIB    T4a     N0       M0
  IIC                 T4b                 N0       M0      IIC    T4b     N0       M0
  IIIA                T1-2                N1/N1c   M0      IIIA   T1-2    N1/N1c   M0
  T1                  N2a                 M0       T1      N2a    M0               
  IIIB                T3-4a               N1/N1c   M0      IIIB   T3-4a   N1/N1c   M0
  T2-3                N2a                 M0       T2-3    N2a    M0               
  T1-2                N2b                 M0       T1-2    N2b    M0               
  IIIC                T4a                 N2a      M0      IIIC   T4a     N2a      M0
  T3-4a               N2b                 M0       T3-4a   N2b    M0               
  T4b                 N1-2                M0       T4b     N1-2   M0               
  IVA                 Any T               Any N    M1a     IVA    Any T   Any N    M1a
  IVB                 Any T               Any N    M1b     IVB    Any T   Any N    M1b
                                                           IVC    Any T   Any N    M1c

###### 

American Joint Committee on Cancer 8^th^ edition updates for the colorectal cancer staging system

  **Update points**                                                 **Update details**                                                                                                                                                     **Level of evidence**
  ----------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------
  Definition of distant transfer (M)                                Introduction of M1c, specifically peritoneal metastasis, is an indicator of poor prognosis                                                                             I
  Definition of regional lymph nodes (N)                            Further introduce the definition of tumor deposit                                                                                                                      II
  Recommended additional indicators for guiding clinical practice   Lymphatic vessel infiltration: Reintroducing the meaning of L and V[1](#T3FN1){ref-type="table-fn"} positive to correctly understand lymphatic and vascular invasion   I
  Recommended additional indicators for guiding clinical practice   Microsatellite instability: Further explaining its importance as a prognostic risk and efficacy predictor                                                              I
  Recommended additional indicators for guiding clinical practice   Determine the *KRAS*, *NRAS*, and *BRAF* mutations as very important prognostic risk and efficacy predictors                                                           I, II

L-positive infiltrates for medics and V-positive for venous infiltration.

The increased complexity of the AJCC-8^th^ staging model was intended to improve the prognostic staging of CRC, but the impact of these changes remains unclear. In this study, we used data from our institutional registries to compare the prognostic accuracy of criteria from AJCC-7^th^ and AJCC-8^th^ in patients with stage 0-IV through survival models. We also explored the relationship between positive node and tumor size, differentiation, tumor invasion, chemotherapy, tumor-node-metastasis (TNM) staging from AJCC-7^th^, and TNM staging from AJCC-8^th^. In addition, we also discussed the pathological importance of lymph invasion, vein invasion, and nerve invasion according to AJCC-8^th^.

MATERIALS AND METHODS
=====================

Patients
--------

A total of 2080 patients with pathologically confirmed stage 0-IV CRC between 2006 and 2012 were collected from our institutional database. Then the following inclusion and exclusion criteria were applied to this cohort: (1) on the basis of a colonoscopy, computed tomography, pathological diagnosis of CRC, in or outside the hospital diagnosis in our hospital; (2) patients undergoing colorectal surgery in our hospital (including radical surgery and non-radical surgery); (3) diagnosis as a recurrence of the primary tumor or as a result of the death of the primary tumor; (4) cases with complete and detailed clinical and pathological data; and (5) cases with complete follow-up data and accurate data. Exclusion criteria were: (1) a serious heart, brain, liver, or lung disease led to intolerant surgery; (2) the non-CRC factors that led to the death of the pathological interstitial tumor, neuronal tumor, lymphoma, melanoma and other non-adenocarcinoma in addition to other malignant tumors; and (3) cases with incomplete clinical-pathologic data and cases with incomplete follow-up data. As a result, 990 cases were excluded. Therefore our analysis focused on the remaining 1090 cases.

Follow-up
---------

Patients were routinely followed in the outpatient clinic 2 wk after surgery for 3 mo and every 3 mo for the first year, then every 6 mo for the second year and every year for the next 3 year. Follow-up data was complemented by phone contact as well as contact with written mail.

Ethics statement
----------------

This study was carried out in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the ethics committee of Huzhou Central Hospital.

Preliminary processing of data
------------------------------

Using the extent of disease codes, tumor invasion (T staging), lymph node positivity (N staging), tumor metastasis (M staging) status, CRC was staged based on the AJCC-7^th^ and AJCC-8^th^ (Table [4](#T4){ref-type="table"}). The patients were divided into three groups (N0, N1, N2) by the number of positive lymph nodes. Clinicopathological data were analyzed between the three groups. Patient status was designated into three outcome categories for disease-free survival (DFS): (1) death from CRC; (2) recurrence from CRC; or (3) alive at the last follow-up. Patient status was designated into two outcome categories for overall survival (OS): (1) death from CRC; or (2) alive at the last follow-up.

###### 

Two-way classification table of staging based on tumor-node-metastasis staging from AJCC-7^th^ *vs* tumor-node-metastasis staging from AJCC-8^th^ for patients with stages 0-IV colorectal cancer from 2006-2012 (*n* = 1090)

                                **TNM staging from AJCC-7^th^**   **Total**                                                       
  ----------------------------- --------------------------------- ----------- ----- ----- ---- ----- ----- ----- ----- ---- ----- ------
  TNM staging from AJCC-8^th^   0                                 16          0     0     0    0     0     0     0     0    0     16
  I                             0                                 131         0     0     0    0     0     0     0     0    131   
  IIA                           0                                 0           138   0     0    0     0     0     0     0    138   
  IIB                           0                                 0           0     56    0    0     0     0     0     0    56    
  IIC                           0                                 0           0     0     31   0     0     0     0     0    31    
  IIIA                          0                                 0           0     0     0    136   0     0     0     0    136   
  IIIB                          0                                 0           0     0     0    0     400   0     0     0    400   
  IIIC                          0                                 0           0     0     0    0     0     127   0     0    127   
  IVA                           0                                 0           0     0     0    0     0     0     24    0    24    
  IVB                           0                                 0           0     0     0    0     0     0     0     9    9     
  IVC                           0                                 0           0     0     0    0     0     0     0     22   22    
                                                                  16          131   138   56   31    136   400   127   24   31    1090

TNM: Tumor-node-metastasis.

Statistical analysis
--------------------

SPSS 21 (Chicago, IL, United States) was used for data analysis. Intergroup measurement data were analyzed using ANOVA analysis of variance and count data were analyzed using Cross-Tab χ^2^ analysis.

The relationship between positive lymph node and tumor size, differentiation, tumor invasion, chemotherapy, and TNM staging from AJCC-7^th^, and TNM staging from AJCC-8^th^ were analyzed by linear and automatic linear regression and the functional equations were established.

Survival curves were generated using Kaplan-Meier estimates, and 5-year DFS and OS were compared using the Log-rank test. Kaplan-Meier was also used to calculate the survival rate of DFS and OS in each group. Afterwards, Cross-table was used to compare the DFS and OS survival rates of sub-periods between AJCC-7^th^ and AJCC-8^th^ groups, and a histogram was generated. *P*-values less than 0.05 were considered statistically significant.

RESULTS
=======

Lymph staging (N) and clinicopathologic characteristics
-------------------------------------------------------

During the 6-year study period, 2080 patients with stage 0-IV CRC were identified but only 1090 met our inclusion criteria. The median age at diagnosis was 66 years \[interquartile range (IQR): 55-73\] and median follow-up was 60 mo (IQR: 54-60). The N staging did not change between AJCC-7^th^ and AJCC-8^th^, therefore we used N staging to analyze clinical pathology data. Patient demographics and pathological features were summarized in Table [5](#T5){ref-type="table"}. This table also compared staging of CRC with AJCC-7^th^ *vs* AJCC-8^th^ criteria. Although there was no difference in the total number of patients with stage IV CRC, the distribution of patients in this period was different. The χ^2^ test was performed for all sub-stages of CRC, and significance exited between IVA and IVB according to AJCC-7^th^ (*P =* 0.001), and between IVA, IVB, and IVC according to AJCC-8^th^ (*P =* 0.05).

###### 

Demographic and clinical characteristics of patients with stage 0-IV colorectal cancer from 2006-2012 (*n*, mean ± SD)

                             **N0**           **N1**           **N2**            **F or χ^2^**   ***P***
  -------------------------- ---------------- ---------------- ----------------- --------------- ----------
  Gender                                                                         2.895           0.235
  Male                       242              182              126                               
  Female                     234              201              105                               
  Age (yr)                   62.46 ± 14.43    62.17 ± 14.43    61.98 ± 14.70     0.095           0.909
  ASA                                                                            6.011           0.198
  1                          362              277              158                               
  2                          102              94               68                                
  3                          12               12               5                                 
  Primary site                                                                   4.94            0.895
  Ileocecum                  36               26               11                                
  Right colon                43               30               22                                
  Transverse colon           70               64               40                                
  Left colon                 88               72               46                                
  Sigmoid colon              53               34               21                                
  Rectum                     186              157              91                                
  Tumor size (cm)            3.31 ± 1.17      3.76 ± 0.82      4.11 ± 0.74       56.008          \< 0.001
  Operation method                                                               8.233           0.411
  RHC                        97               67               43                                
  LHC                        186              154              91                                
  HO                         9                6                9                                 
  AR                         145              112              70                                
  APR                        39               44               18                                
  Operation time (m)         151.59 ± 36.31   156.40 ± 34.94   153.17 ± 31.30    2.044           0.130
  Resection length (cm)      27.96 ± 9.92     27.26 ± 9.83     27.65 ± 9.92      0.533           0.587
  Blood loss (mL)            184.39 ± 94.25   185.23 ± 95.26   194.30 ± 107.32   0.879           0.416
  Tumor invasion                                                                 131.640         \< 0.001
  Tis                        16               0                0                                 
  T1                         85               17               9                                 
  T2                         92               75               43                                
  T3                         162              127              132                               
  T4a                        82               108              22                                
  T4b                        39               56               25                                
  Differentiation                                                                188.64          \< 0.001
  Well                       150              31               13                                
  Moderate                   276              296              124                               
  Poor or undifferentiated   50               56               94                                
  Number of LNs examined     14.70 ± 1.88     14.13 ± 1.78     14.26 ± 1.85      0.408           0.665
  Number of positive LNs     0                1.85 ± 0.73      5.46 ± 1.64       3050.47         \< 0.001
  Complication                                                                   4.088           0.130
  No                         436              349              201                               
  Yes                        40               34               30                                
  Chemotherapy                                                                   295.36          \< 0.001
  Yes                        283              383              229                               
  No                         193              0                2                                 
  TNM staging AJCC-7^th^                                                         887.08          \< 0.001
  0                          16               0                0                                 
  I                          131              0                0                                 
  IIA                        138              0                0                                 
  IIB                        56               0                0                                 
  IIC                        31               0                0                                 
  IIIA                       45               82               9                                 
  IIIB                       49               234              117                               
  IIIC                       9                47               71                                
  IVA                        1                15               8                                 
  IVB                        0                5                26                                
  TNM staging AJCC-8^th^                                                         887.32          \< 0.001
  0                          16               0                0                                 
  I                          131              0                0                                 
  IIA                        138              0                0                                 
  IIB                        56               0                0                                 
  IIC                        31               0                0                                 
  IIIA                       45               82               9                                 
  IIIB                       49               234              117                               
  IIIC                       9                47               71                                
  IVA                        1                15               8                                 
  IVB                        0                1                8                                 
  IVC                        0                4                18                                

TNM: Tumor-node-metastasis.

***Linear model between the number of positive lymph nodes and tumor size, differentiation, tumor invasion, chemotherapy, TNM staging from AJCC-7^th^, and TNM staging from AJCC-8^th^***

The number of positive lymph nodes was related to the N anatomical stages in AJCC-7^th^ and AJCC-8^th^. An automated linear model found that the number of positive lymph nodes and tumor size, tumor differentiation, depth of tumor invasion, chemotherapy, TNM staging from AJCC-7^th^, and TNM staging from AJCC-8^th^ were indicators of good fit and showed significance (*P* \< 0.05). The fitting degree for TNM staging from AJCC-7^th^ was 61.3% (Figure [2A](#F2){ref-type="fig"}), and the index that had a significant influence on positive lymph nodes was shown in Figure [2B](#F2){ref-type="fig"}. However, chemotherapy was not included in the predictive importance index (Figure [2C](#F2){ref-type="fig"}). The importance of TNM staging from AJCC-7^th^ was 77%, and the importance of tumor invasion was 19%, the importance of tumor size was 3%, the degree of tumor differentiation was 1%. Figure [2D](#F2){ref-type="fig"} showed significant parameters of each coding amount and constant coefficient. The fitness for TNM staging from AJCC-8^th^ was 63.3% (Figure [3A](#F3){ref-type="fig"}), and the indexes that had a significant influence on positive lymph nodes were shown in Figure [3B](#F3){ref-type="fig"}. Chemotherapy was also included in the predictive importance index (Figure [3C](#F3){ref-type="fig"}). The importance of TNM staging from AJCC-8^th^ was 72%, the importance of tumor invasion was 20%, the importance of chemotherapy was 4%, the importance of tumor size was 3%, the degree of tumor differentiation was 1%. Figure [3D](#F3){ref-type="fig"} showed significant parameters of each coding amount and constant coefficient.

![Automatic linear regression about positive lymph nodes and clinicopathologic parameters with tumor-node-metastasis staging from AJCC-7^th^. A: Clinical pathological parameters fitting degree. Fitting value is 61.3%; B: Significant effect parameters (*P* \< 0.05); C: Predictor importance of positive lymph nodes and clinicopathological parameters. The values of tumor-node-metastasis staging from AJCC-7^th^, tumor invasion, tumor size, and differentiation are 0.77, 0.19, 0.03, and 0.01, respectively; D: Coefficients about positive nodes and clinicopathological parameters.](WJCO-9-148-g002){#F2}

![Automatic linear regression about positive lymph nodes and clinicopathologic parameters with tumor-node-metastasis staging from AJCC-8^th^. A: Clinical pathological parameters fitting degree. The fitting value is 63.3%; B: Significant effect parameters (*P* \< 0.05); C: Predictor importance of positive lymph nodes and clinicopathological parameters. The values of tumor-node-metastasis staging from AJCC-8^th^, tumor invasion, chemotherapy, tumor size, and differentiation are 0.72, 0.2, 0.04, 0.03 and 0.01, respectively; D: Coefficients about positive nodes and clinicopathological parameters.](WJCO-9-148-g003){#F3}

Then the linear model calculated the functional equation for these variables and positive lymph node relationships. Outcome showed that Y~A~ = -0.918 + 0.409X~B~ + 0.18X~C~ - 0.583X~D~ - 0.460X~E~ + 0.669X~F~ and Y~A~ = -0.821 + 0.404X~B~ + 0.183X~C~ - 0.587X~D~ - 0.491X~E~ + 0.658X~G~ (A: Positive lymph node; B: Tumor size; C: Differentiation; D: Tumor invasion; E: Chemotherapy; F: TNM staging from AJCC-7^th^; G: TNM staging from AJCC-8^th^).

DFS and OS between AJCC-7^th^ and AJCC-8^th^ criteria
-----------------------------------------------------

Using Kaplan-Meier univariate analysis and Log-rank test, the 5-year survival rate of DFS and OS in 1090 patients was calculated and compared by stage and sub-stage according AJCC-7^th^ and AJCC-8^th^ criteria. DFS and OS survival rate between the two editions did not change from stage 0-IV and from substage 0-IVB. However, when the 5-year DFS and OS survival rate were compared from stage IVB from AJCC-7^th^ and from stage IVB and IVC from AJCC-8^th^ the survival curve of DFS and OS showed a significant right shift for stage IVB and a significant left shift for stage IVC (*P =* 0.001 and *P* \< 0.001, respectively). Details were shown in Table [6](#T6){ref-type="table"} and Figure [4](#F4){ref-type="fig"}.

![Disease-free survival and overall survival curves and histograms between tumor-node-metastasis staging from AJCC-7^th^ and tumor-node-metastasis staging from AJCC-8^th^. A: Comparison of 5-year disease-free survival (DFS) by sub-stage from AJCC-7^th^ (*P* \< 0.001); B: Comparison of 5-year DFS by sub-stage from AJCC-8^th^ (*P* \< 0.001); C: Comparison of 5-year overall survival (OS) by sub-stage from AJCC-7^th^ (*P* \< 0.001); D: Comparison of 5-year OS by sub-stage for from AJCC-8^th^ (*P* \< 0.001); E: Comparison of 5-year DFS by stage from AJCC-7^th^ (*P* \< 0.001); F: Comparison of 5-year DFS by stage from AJCC-8^th^ (*P*\<0.001); G: Comparison of 5-year OS by stage from AJCC-7^th^ (*P* \< 0.001); H: Comparison of 5-year OS by stage for from AJCC-8^th^ (*P* \< 0.001); A *vs* B and C *vs* D: Survival curves of DFS and OS in stage IVB shift right and those in stage IVC shift left; I-L: Comparison of DFS and OS by sub-stage and stage between staging from AJCC-7^th^ and staging from AJCC-8^th^, all *P* \< 0.01. DFS: Disease-free survival; OS: Overall survival; TNM: Tumor-node-metastasis.](WJCO-9-148-g004){#F4}

###### 

Comparison of 5-year disease-free survival and overall survival rate for stage and sub-stage using American Joint Committee on Cancer-7^th^ edition and American Joint Committee on Cancer-8^th^ edition (%)

                                **0**   **I**   **IIA**   **IIB**   **IIC**   **IIIA**   **IIIB**   **IIIC**   **IVA**   **IVB**   **IVC**   **Log-rank χ^2^**   ***P***
  -------- ----------- -------- ------- ------- --------- --------- --------- ---------- ---------- ---------- --------- --------- --------- ------------------- ---------
  OS       Sub-stage   AJCC-7   100     98.5    82.6      76.8      67.7      65.4       60         44.9       8.3       0         \-        1423.53             \< 0.01
  AJCC-8   100         98.5     82.6    76.8    67.7      65.4      60        44.9       8.3        0          0         1608.11   \< 0.01                       
                                        II      III       IV                                                                                                     
  Stage    AJCC-7      100      98.5    79.1    58.2      3.6       913.56    \< 0.01                                                                            
  AJCC-8   100         98.5     79.1    58.2    3.6       875.46                                                                                                 
  DFS      Sub-stage   AJCC-7   100     93.1    78.3      73.2      61.3      65.4       56.3       37         8.3       0         \-        1418.9              \< 0.01
  AJCC-8               93.1     78.3    73.2    61.3      65.4      56.3      37         8.3        0          0         1603.4    \< 0.01                       
                                        II      III       IV                                                                                                     
  Stage    AJCC-7      100      93.1    74.7    54.4      3.6       875.46    \< 0.01                                                                            
  AJCC-8               93.1     74.7    54.4    3.6       875.46    \< 0.01                                                                                      

DFS: Disease-free survival; OS: Overall survival; AJCC: American Joint Committee on Cancer.

Nerve invasion, vein invasion, Lymphatic invasion and tumor deposit between AJCC-7^th^ and AJCC-8^th^
-----------------------------------------------------------------------------------------------------

AJCC-8^th^ further emphasized the clinical value of tumor lymphatic invasion, vein invasion, nerve invasion, and tumor deposit (TD) and were included in "evidence-based medicine" evidence level (Table [3](#T3){ref-type="table"}). Since the release of AJCC-7^th^, our institution's pathologist has attached great importance to this aspect of the test and has described them in detail (Figure [5](#F5){ref-type="fig"}).

![The focus of the eighth edition of the American Joint Committee on Cancer pathology test description. A: Tumor deposit; B: Lymphatic invasion; C: Vein invasion; D: Nerve invasion.](WJCO-9-148-g005){#F5}

DISCUSSION
==========

In 1977, AJCC established the first edition of the cancer staging system. Revision to the system have been made every 6-8 years and until recently it has been regarded as the most comprehensive tool for prognostic and predictive grouping of patients with colon cancer\[[@B24]\]. However, when AJCC-6^th^ was released in 2002\[[@B27]\], it elicited criticism because survival of patients with stage IIIA colon cancer was superior to that of patients with stage IIB colon cancer\[[@B28]\]. In 2010, the AJCC cancer staging system was updated to the 7^th^ edition\[[@B22],[@B29]\]. This edition included both the refinement of the classic TNM "anatomic blood" diagnostic system, the increase in tumor regression scores, and the risk of prognoses and curative effects for circumferential resection margins.

Evaluation index
----------------

The problem with AJCC staging of CRC was initially attributed to inadequate lymph node (LN) assessment. Previous studies demonstrated that the number of examined LNs impacted survival\[[@B30]-[@B34]\]. Subsequent studies showed a strong correlation between outcomes and compliance with 12-LN minimum\[[@B35]-[@B39]\]. In our study, in addition to analyzing the distribution of LN numbers in different N stages, we also focused on the effect of positive LN numbers on lymphatic pathology, and established a linear function.

In recent years, researchers have recognized the importance of tumorigenesis and the role of non-anatomic markers in establishing the prognosis and anticipated response to therapy\[[@B40]-[@B45]\]. Of these factors, the circumferential margin of the resected non-peritonealized surface of the specimen (CRM) is relevant for prognostic assessment of patients with tumors in the ascending and descending colon\[[@B46],[@B47]\]. Microsatellite instability, KRAS mutation and the 18q LOH have been shown to have clinical prognostic significance\[[@B48],[@B49]\]. These factors have not been incorporated into the staging system because it is not clear how they should be used to determine prognosis or the need for adjuvant chemotherapy. In 2013, AJCC established the "Evidence-Based Medicine and Statistics Core Group" of the eighth edition system, which was responsible for determining the level of evidence for any updated content of the AJCC staging system. New evidence had to reach an evidence quality level of I-III to be factored into the staging system for the eighth edition.

AJCC-8^th^ did not include any updates for tumor staging. The definition of TD and N1c in the N-stage was further interpreted as the presence of encouraging tumor nodules in the lymphatic drainage area of the primary tumor, and no lymph node, vessel, or nerve structure identified during the period. The presence of TD did not alter the T stage of the primary tumor, but if it was not accompanied by lymph node metastasis, the TDs would change N stage (from N0 to N1c). If there was combined lymph node metastasis, the number of TDs did not need to be counted in the number of positive lymph nodes. The latest version reaffirmed the definition of lymphatic infiltrating vessels. Any vessel lesions with or without residual vascular walls could be identified as lymphocytic infiltrates in storage vessels and become a routine item in the pathology report of the American College of Pathology. Our institutional pathologist recognized this and described them in the report (Figure [5](#F5){ref-type="fig"}). Vascular lymphatic infiltration could be subdivided into small vessel infiltration (lymphatic or venular infiltration, defined as "L" positive) and venous infiltration (a structure surrounded by tumor immersion and endothelial cells, which contain red blood cells coated with smooth muscle machinery was defined as "V" positive). At the same time, it was found that tumor immersion and nerve tissue were defined as infiltration around the nerve. Lymphatic infiltration and perineural invasion were both important prognostic factors\[[@B50]-[@B56]\].

AJCC-7^th^ classified the metastasis stage M1 as M1a (metastasis in one organ or site) and M1b (metastasis in more than one organ or site, or in the peritoneum). In AJCC-8^th^, another stage was added to describe colorectal peritoneal metastases (whether or not with metastasis of other organ sites). This is called M1c, and M1a and M1b were redefined as metastasis limited to one organ or site (such as liver, lung, ovary, extra-nodal lymph nodes, *etc*.) and transition beyond one organ or site, but without peritoneal metastasis, respectively. The reason for the change is that although peritoneal metastasis occur in 1% to 4% of patients with CRC, the prognosis is far worse than that of M1a and M1b patients who have metastasis of substantial organs\[[@B57]-[@B61]\].

We reclassified our cohort according to the AJCC-8^th^ criteria. The results showed that the DFS and OS of the M1a stage remained unchanged, while that of the M1b stage improved, and that of the M1c stage decreased significantly. This demonstrated that the M stage refinement was necessary. This additional classification in the eighth edition will have a positive and far-reaching effect on cancer treatment that will promote the individualized diagnosis and treatment of CRC patients. However, further analysis with additional institutional databases is needed to confirm our findings.

In conclusion, the addition of a sub-stage to classify peritoneal metastasis separately from distant organ metastasis in the AJCC-8^th^ manual has shown that peritoneal metastasis has a worse prognosis than organ metastasis in our cohort.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Colorectal cancer (CRC) is a common malignant tumors. Clinicians have been using the American Joint Committee on Cancer (AJCC) system to guide clinical diagnosis and treatment for CRC. The eighth edition of the AJCC (AJCC-8^th^) has received extensive attention since its promulgation in 2016. Compared to the previous version, AJCC-8^th^ refined the stage IV classification to separate peritoneal metastasis and organ metastasis.

Research motivation
-------------------

In China, there are still many hospital surgeons and physicians who still use the old version to guide clinical practice and are uneducated about the new AJCC-8^th^ classifications.

Research objectives
-------------------

We analyzed our institution's CRC cohort to determine differences in the survival trends based on the diagnostic classifications between AJCC-8^th^ and the previous version.

Research methods
----------------

A total 1090 patients of 2080 CRC patients were included in the study. The data were classified by AJCC-7^th^ and AJCC-8^th^ standards. Five-year disease-free survival (DFS) and overall survival (OS) were compared.

Research results
----------------

Linear regression and automatic linear regression showed lymph node positive functional equations by TNM staging from AJCC-7 and TNM staging from AJCC-8^th^. Neurological invasion, venous infiltration, lymphatic infiltration, and tumor deposition put forward stricter requirements for pathological examination. AJCC-8^th^ staging yielded a proportional decrease of IVB from 2.8% to 0.8% and a new staging of IVC to 2%. Log-rank test showed that DFS and OS survival time of patients with IVC *vs* IVB was significantly shorter (*P =* 0.012).

Research conclusions
--------------------

The addition of a sub-stage to classify peritoneal metastasis separately from distant organ metastasis in the AJCC-8^th^ manual has shown that peritoneal metastasis has a worse prognosis than organ metastasis in our cohort. Considering many prognostic factors, individualized treatment is particularly important to improve the survival time of stage IV patients, especially IVC patients.

Research perspective
--------------------

Further studies can be done to improve outcomes for peritoneal metastasis CRC patients. Further analysis of additional institutional databases is needed to confirm our findings.
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